ArticleRevista Cuidarte
Macrolide resistance in Staphylococcus from COVID-19 patients in Santander.
Article in Revista Cuidarte. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Intensive use of macrolides, such as azithromycin, during the COVID-19 pandemic has facilitated the development of antimicrobial resistance in Gram-positive bacteria through multiple resistance mechanisms, including ribosomal RNA modification, efflux pumps, and enzymatic inactivation. Objective: To describe the prevalence of resistance genes in bacteria isolated from COVID-19 patients in Santander, Colombia. Materials and Methods: A descriptive study was conducted on 112 stored samples from nasopharyngeal and oropharyngeal swabs and tracheal aspirates collected from hospitalized COVID-19 patients in 2020, from which 48 Gram-positive strains were isolated. Macrolide resistance and the presence of the ermA, ermB, ermT, and mef(A/E) genes were evaluated through phenotypic and molecular tests. Results: Staphylococcus aureus was the most prevalent species at 58.33% (28), followed by Staphylococcus epidermidis at 31.25% (15). A total of 47.92% (23) of the strains showed phenotypic resistance to azithromycin, and 81.25% (39) displayed genotypic resistance, with ermB being the most prevalent at 58.33% (28) and ermT at 45.83% (22), with no detection of mef(A/E). Discussion: These findings reveal a high prevalence of macrolide resistance, which may be related to the extensive use of these antibiotics during the pandemic. Conclusion: The increase in macrolide resistance among Gram-positive bacteria represents a critical public health challenge, especially in the context of pandemics. These results underscore the urgent need to implement control measures in antibiotic use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.